Skip to main content

Table 4 Number of patients who completed treatment and reasons for discontinuation

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

  Number of patients (%)
  DD/DI arm (N = 86) HDI arm(N = 80)
Completed therapy 54 (63) 32 (40)
Reasons for discontinuation     
Toxicity 11 (13) 14 (17)
Refusal 11 (13) 15 (19)
Disease Progression 10 (12) 19 (24)